Liquid Biopsy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Global Liquid Biopsy Market was valued at USD 4.8 billion in 2024 and is estimated to grow at a CAGR of 15.8% to reach USD 20.7 billion by 2034.
The growth is being fueled by rising advancements in cancer diagnostics, a shift toward non-invasive methods, increasing cancer prevalence, and greater awareness around early detection. As healthcare systems globally invest in infrastructure and expand screening access, demand for scalable, accurate tools like liquid biopsy continues to accelerate. The growing focus on early-stage identification and precision medicine is creating fertile ground for the integration of liquid biopsy into clinical settings. The test allows the detection and analysis of tumor-derived biomarkers such as cell-free DNA, circulating tumor cells, and extracellular vesicles directly from bodily fluids, offering a safer and faster alternative to traditional tissue biopsies. With applications spanning cancer diagnosis, mutation tracking, and treatment monitoring, liquid biopsy is proving to be a transformative solution, especially for high-risk and vulnerable patient populations. Its ability to minimize procedural risks while delivering actionable insights supports broader adoption across research institutions, hospitals, and diagnostic labs.
In 2024, the circulating tumor cells segment generated USD 1.9 billion. These cells, which detach from primary tumors and travel through the bloodstream, are valuable in revealing tumor dynamics in real time. Technologies used to isolate and analyze CTCs, ranging from imaging platforms to microfluidics, are enabling clinicians to understand tumor evolution, resistance mechanisms, and genetic profiles. Their non-invasive nature and role in real-time monitoring make CTCs an increasingly important component of the liquid biopsy ecosystem, broadening its clinical relevance.
The cancer application segment held an 85.8% share in 2024. The steadily rising global burden of cancer continues to elevate the demand for faster, less invasive, and highly precise diagnostic methods. Liquid biopsy offers the potential to detect malignancies earlier, tailor therapies more effectively, and monitor responses without requiring surgical interventions. Its growing adoption in oncology is being driven by the need for more personalized, patient-centric treatment strategies that reduce time-to-diagnosis and improve care outcomes.
North America Liquid Biopsy Market generated USD 2 billion in 2024 and is expected to reach USD 8.4 billion by 2034. The region’s leadership stems from its strong biotechnology research ecosystem, significant government investments in oncology, and rising demand for advanced diagnostic options. High adoption rates across clinical and research environments, along with regular product innovation and approvals, are helping solidify the region’s position. Rising awareness among patients and providers, along with robust R&D pipelines supported by public and private funding, is adding momentum to regional growth.
Key players shaping the Global Liquid Biopsy Market include Myriad Genetics, BIOCEPT, Thermo Fisher Scientific, Guardant Health, F. Hoffmann La Roche, Menarini Silicon Biosystems, Lucene Health, Oncimmune, Illumina, EPIGENOMICS, Freenome Holdings, QIAGEN, Bio-Rad Laboratories, MDxHealth, and Angle. Companies in the Liquid Biopsy Market are deploying multi-faceted strategies to build and protect their market positions. A primary focus lies in expanding R&D pipelines for early-stage cancer detection and monitoring solutions. Strategic collaborations with research institutes and hospitals help accelerate clinical validation and widen access to emerging technologies. Many firms are developing AI-driven platforms to improve the accuracy of biomarker detection and streamline interpretation.
The growth is being fueled by rising advancements in cancer diagnostics, a shift toward non-invasive methods, increasing cancer prevalence, and greater awareness around early detection. As healthcare systems globally invest in infrastructure and expand screening access, demand for scalable, accurate tools like liquid biopsy continues to accelerate. The growing focus on early-stage identification and precision medicine is creating fertile ground for the integration of liquid biopsy into clinical settings. The test allows the detection and analysis of tumor-derived biomarkers such as cell-free DNA, circulating tumor cells, and extracellular vesicles directly from bodily fluids, offering a safer and faster alternative to traditional tissue biopsies. With applications spanning cancer diagnosis, mutation tracking, and treatment monitoring, liquid biopsy is proving to be a transformative solution, especially for high-risk and vulnerable patient populations. Its ability to minimize procedural risks while delivering actionable insights supports broader adoption across research institutions, hospitals, and diagnostic labs.
In 2024, the circulating tumor cells segment generated USD 1.9 billion. These cells, which detach from primary tumors and travel through the bloodstream, are valuable in revealing tumor dynamics in real time. Technologies used to isolate and analyze CTCs, ranging from imaging platforms to microfluidics, are enabling clinicians to understand tumor evolution, resistance mechanisms, and genetic profiles. Their non-invasive nature and role in real-time monitoring make CTCs an increasingly important component of the liquid biopsy ecosystem, broadening its clinical relevance.
The cancer application segment held an 85.8% share in 2024. The steadily rising global burden of cancer continues to elevate the demand for faster, less invasive, and highly precise diagnostic methods. Liquid biopsy offers the potential to detect malignancies earlier, tailor therapies more effectively, and monitor responses without requiring surgical interventions. Its growing adoption in oncology is being driven by the need for more personalized, patient-centric treatment strategies that reduce time-to-diagnosis and improve care outcomes.
North America Liquid Biopsy Market generated USD 2 billion in 2024 and is expected to reach USD 8.4 billion by 2034. The region’s leadership stems from its strong biotechnology research ecosystem, significant government investments in oncology, and rising demand for advanced diagnostic options. High adoption rates across clinical and research environments, along with regular product innovation and approvals, are helping solidify the region’s position. Rising awareness among patients and providers, along with robust R&D pipelines supported by public and private funding, is adding momentum to regional growth.
Key players shaping the Global Liquid Biopsy Market include Myriad Genetics, BIOCEPT, Thermo Fisher Scientific, Guardant Health, F. Hoffmann La Roche, Menarini Silicon Biosystems, Lucene Health, Oncimmune, Illumina, EPIGENOMICS, Freenome Holdings, QIAGEN, Bio-Rad Laboratories, MDxHealth, and Angle. Companies in the Liquid Biopsy Market are deploying multi-faceted strategies to build and protect their market positions. A primary focus lies in expanding R&D pipelines for early-stage cancer detection and monitoring solutions. Strategic collaborations with research institutes and hospitals help accelerate clinical validation and widen access to emerging technologies. Many firms are developing AI-driven platforms to improve the accuracy of biomarker detection and streamline interpretation.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Data mining sources
1.3.1 Global
1.3.2 Regional/Country
1.4 Base estimates and calculations
1.4.1 Base year calculation
1.4.2 Key trends for market estimation
1.5 Primary research and validation
1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Biomarkers trends
2.2.3 Product trends
2.2.4 Disease indication trends
2.2.5 Clinical application trends
2.2.6 Technology trends
2.2.7 End use trends
2.3 CXO perspectives: Strategic imperatives
2.3.1 Key decision points for industry executives
2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Continuous technological advancements in cancer diagnostics
3.2.1.2 Increasing preference for non-invasive disease diagnosis
3.2.1.3 Growing prevalence of cancer worldwide
3.2.1.4 Rising awareness regarding early disease diagnosis
3.2.2 Industry pitfalls and challenges
3.2.2.1 Stringent regulatory framework
3.2.2.2 Lack of skilled professionals
3.2.3 Market opportunities
3.2.3.1 Expansion of multi-cancer early detection (MCED) tests
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 North America
3.4.2 Europe
3.4.3 Asia Pacific
3.4.4 Latin America
3.4.5 Middle East and Africa
3.5 Technological advancements
3.5.1 Current technological trends
3.5.2 Emerging technologies
3.6 Supply chain analysis
3.7 Reimbursement scenario
3.8 Pricing analysis, 2024
3.9 Future market trends
3.10 Gap analysis
3.11 Porter's analysis
3.12 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Mergers and acquisitions
4.6.2 Partnerships and collaborations
4.6.3 New product launches
4.6.4 Expansion plans
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY BIOMARKERS, 2021 - 2034 ($ MN)
5.1 Key trends
5.2 Circulating tumor cells (CTC)
5.3 Circulating tumor DNA
5.4 Cell-free DNA
5.5 Extracellular vesicles
5.6 Other biomarkers
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY PRODUCT, 2021 - 2034 ($ MN)
6.1 Key trends
6.2 Consumables
6.2.1 Kits and reagents
6.2.2 Assay and panels
6.3 Instruments
6.4 Services
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY DISEASE INDICATION, 2021 - 2034 ($ MN)
7.1 Key trends
7.2 Cancer
7.2.1 Lung cancer
7.2.2 Breast cancer
7.2.3 Colorectal cancer
7.2.4 Prostate cancer
7.2.5 Other cancers
7.3 Non-cancer
7.3.1 Non-invasive prenatal testing
7.3.2 Organ transplantation
7.3.3 Infectious disease testing
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY CLINICAL APPLICATION USE, 2021 - 2034 ($ MN)
8.1 Key trends
8.2 Treatment monitoring
8.3 Prognosis and recurrence monitoring
8.4 Treatment selection
8.5 Diagnosis and screening
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY TECHNOLOGY, 2021 - 2034 ($ MN)
9.1 Key trends
9.2 Multi-gene parallel analysis (NGS)
9.3 Single gene analysis (PCR Microarrays)
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 - 2034 ($ MN)
10.1 Key trends
10.2 Hospitals
10.3 Research Laboratories
10.4 Clinical Laboratories
10.5 Other end use
CHAPTER 11 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 - 2034 ($ MN)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Netherlands
11.4 Asia Pacific
11.4.1 China
11.4.2 India
11.4.3 Japan
11.4.4 Australia
11.4.5 South Korea
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Argentina
11.6 Middle East and Africa
11.6.1 Saudi Arabia
11.6.2 South Africa
11.6.3 UAE
CHAPTER 12 COMPANY PROFILES
12.1 Angle
12.2 BIOCEPT
12.3 Bio-Rad Laboratories
12.4 EPIGENOMICS
12.5 F. Hoffmann La Roche
12.6 Freenome Holdings
12.7 Guardant Health
12.8 Illumina
12.9 Lucene Health
12.10 MDxHealth
12.11 Menarini Silicon Biosystems
12.12 Myriad Genetics
12.13 Oncimmune
12.14 QIAGEN
12.15 Thermo Fisher Scientific
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Data mining sources
1.3.1 Global
1.3.2 Regional/Country
1.4 Base estimates and calculations
1.4.1 Base year calculation
1.4.2 Key trends for market estimation
1.5 Primary research and validation
1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Biomarkers trends
2.2.3 Product trends
2.2.4 Disease indication trends
2.2.5 Clinical application trends
2.2.6 Technology trends
2.2.7 End use trends
2.3 CXO perspectives: Strategic imperatives
2.3.1 Key decision points for industry executives
2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Continuous technological advancements in cancer diagnostics
3.2.1.2 Increasing preference for non-invasive disease diagnosis
3.2.1.3 Growing prevalence of cancer worldwide
3.2.1.4 Rising awareness regarding early disease diagnosis
3.2.2 Industry pitfalls and challenges
3.2.2.1 Stringent regulatory framework
3.2.2.2 Lack of skilled professionals
3.2.3 Market opportunities
3.2.3.1 Expansion of multi-cancer early detection (MCED) tests
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 North America
3.4.2 Europe
3.4.3 Asia Pacific
3.4.4 Latin America
3.4.5 Middle East and Africa
3.5 Technological advancements
3.5.1 Current technological trends
3.5.2 Emerging technologies
3.6 Supply chain analysis
3.7 Reimbursement scenario
3.8 Pricing analysis, 2024
3.9 Future market trends
3.10 Gap analysis
3.11 Porter's analysis
3.12 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Mergers and acquisitions
4.6.2 Partnerships and collaborations
4.6.3 New product launches
4.6.4 Expansion plans
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY BIOMARKERS, 2021 - 2034 ($ MN)
5.1 Key trends
5.2 Circulating tumor cells (CTC)
5.3 Circulating tumor DNA
5.4 Cell-free DNA
5.5 Extracellular vesicles
5.6 Other biomarkers
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY PRODUCT, 2021 - 2034 ($ MN)
6.1 Key trends
6.2 Consumables
6.2.1 Kits and reagents
6.2.2 Assay and panels
6.3 Instruments
6.4 Services
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY DISEASE INDICATION, 2021 - 2034 ($ MN)
7.1 Key trends
7.2 Cancer
7.2.1 Lung cancer
7.2.2 Breast cancer
7.2.3 Colorectal cancer
7.2.4 Prostate cancer
7.2.5 Other cancers
7.3 Non-cancer
7.3.1 Non-invasive prenatal testing
7.3.2 Organ transplantation
7.3.3 Infectious disease testing
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY CLINICAL APPLICATION USE, 2021 - 2034 ($ MN)
8.1 Key trends
8.2 Treatment monitoring
8.3 Prognosis and recurrence monitoring
8.4 Treatment selection
8.5 Diagnosis and screening
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY TECHNOLOGY, 2021 - 2034 ($ MN)
9.1 Key trends
9.2 Multi-gene parallel analysis (NGS)
9.3 Single gene analysis (PCR Microarrays)
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 - 2034 ($ MN)
10.1 Key trends
10.2 Hospitals
10.3 Research Laboratories
10.4 Clinical Laboratories
10.5 Other end use
CHAPTER 11 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 - 2034 ($ MN)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Netherlands
11.4 Asia Pacific
11.4.1 China
11.4.2 India
11.4.3 Japan
11.4.4 Australia
11.4.5 South Korea
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Argentina
11.6 Middle East and Africa
11.6.1 Saudi Arabia
11.6.2 South Africa
11.6.3 UAE
CHAPTER 12 COMPANY PROFILES
12.1 Angle
12.2 BIOCEPT
12.3 Bio-Rad Laboratories
12.4 EPIGENOMICS
12.5 F. Hoffmann La Roche
12.6 Freenome Holdings
12.7 Guardant Health
12.8 Illumina
12.9 Lucene Health
12.10 MDxHealth
12.11 Menarini Silicon Biosystems
12.12 Myriad Genetics
12.13 Oncimmune
12.14 QIAGEN
12.15 Thermo Fisher Scientific
